7 completed, 2 terminated. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 2 |
| Phase 1 | 3 | Completed 3 |
Follow olaratumab: new trials by email Literature Review of olaratumab trials Research Report on olaratumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients Olaratumab, Dexrazoxane, Doxorubicin - Advanced Soft Tissue Sarcoma | Phase 2 | Terminated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 | 2018-11-12 | 2020-07-15 |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Olaratumab, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 184 | 2017-06-22 | 2022-06-28 |
| A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Olaratumab, Gemcitabine, Docetaxel - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 310 | 2016-03-01 | 2022-05-09 |
| A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors Olaratumab - Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Terminated | Eli Lilly and Company | 21 | 2011-08-01 | 2017-03-09 |
| A Study of Olaratumab (IMC-3G3) in Prostate Cancer Olaratumab, Mitoxantrone, Prednisone - Prostate Cancer | Phase 2 | Completed | Eli Lilly and Company | 123 | 2010-10-01 | 2019-09-20 |
| A Study of Olaratumab in Soft Tissue Sarcoma Olaratumab, doxorubicin - Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 148 | 2010-10-01 | 2017-04-14 |
| Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme olaratumab, ramucirumab - Adult Glioblastoma Multiforme | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 80 | 2010-07-01 | 2017-12-27 |
| A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Olaratumab, Paclitaxel, Carboplatin - Non-Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 137 | 2010-01-01 | 2019-01-10 |
| A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer Olaratumab, liposomal doxorubicin - Ovarian Neoplasms | Phase 2 | Completed | Eli Lilly and Company | 125 | 2009-06-01 | 2019-09-26 |
Sarcoma (3) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Gliosarcoma (1) · Lung Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Eli Lilly and Company (7) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (7) · Germany (5) · Spain (4) · Poland (3) · Belgium (2) · Hungary (2) · Italy (2) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Israel (1) · Netherlands (1) · United Kingdom (1)
Jaishri O. Blakeley, MD (1) · Salah-Eddin Al-Batran, Prof. Dr. (1)
PMID 27291997, PMID 28426120, PMID 30591028, PMID 37185961
2009 (2), 2015 (1), 2016 (1), U01CA137443 (1)